Organon & Co. Common Stock (NYSE: OGN)
47 Days left to seek lead plaintiff status.
The Complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Company’s priorities, particularly, related to capital allocation through quarterly dividends. The Complaint further alleges that Defendants concealed the high priority of Organon’s debt reduction strategy following the Company’s acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.